Find trials
Search tips

Assessing Patient Outcomes Following Treatment with Ceftolozane/Tazobactam (C/T)

Overview

About this study

The purpose of this study is to evaluate the real-world utilization of ceftolozane/tazobactam (C/T) and to assess patient outcomes.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

All unique (i.e., first treatment course only):

  • Adult male and female patients (>18 years old) who received at least 48 hours of C/T will be included.

Exclusion Criteria:

  • Patients < 18 years of age or those who received < 48 hours of C/T therapy will be excluded.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Abinash Virk, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20519184

Mayo Clinic Footer